key: cord-0683800-dm67tigb authors: Zhang, X.; Yang, X.; Jiao, H.; Liu, X. title: Coagulopathy in patients with Coronavirus Disease 2019 (COVID-19): A systematic review and meta-analysis date: 2020-07-16 journal: nan DOI: 10.1101/2020.07.15.20154138 sha: eca28179eb64a21ae9725427cf4e06d3c4d5a2c6 doc_id: 683800 cord_uid: dm67tigb Patients with COVID-19 frequently manifest coagulation abnormalities and thrombotic events. In this meta-analysis, we aimed to explore the role of coagulopathy on the severity differences in patients with COVID-19. We conducted systematic literature search via Pubmed, Embase, Cochrane, WanFang Database, CNKI, and medRxiv from December 1, 2019 to May 1, 2020, to identify all original studies that reports on coagulation parameters (D-dimer, PLT, PT, APTT, and FIB) during COVID-19 infection. Thereafter, we compared the coagulation parameters between less severe and more severe cases. All Statistical analyses were performed via Stata14.0 software. A total of 3,952 confirmed COVID-19 infected patients were included from 25 studies. Patients with severe COVID-19 infection exhibited significantly higher levels of D-dimer, PT, and FIB (SMD 0.83, 95% CI: 0.70-0.97, I2 56.9%; SMD 0.39, 95% CI: 0.14-0.64, I2 77.9%; SMD 0.35, 95% CI: 0.17-0.53, I2 42.4% respectively). However, difference in PLT and APTT levels between less severe and more severe patients was not statistically significant (SMD-0.26, 95% CI: -0.56-0.05, I2 82.2%; SMD-0.14,95% CI: -0.45-0.18, I2 75.5% respectively) This meta-analysis revealed coagulopathy is associated with the severity of COVID-19. Notably, D-dimer, PT, and FIB are the dominant parameters that should be considered in evaluating coagulopathy in COVID-19 patients. of which 322 were eliminated for meeting the exclusion criteria. A total of 34 articles were included in the quality evaluation from which 9 were excluded due to low quality (NOS<5). Eventually, we included 25 articles (1 in Chinese and 24 in English) for analyses . The overall quality of available literature was moderate or high with NOS scores ranging from 5-7. The quality evaluation of the 34 articles is shown in Supplementary Table 2. A total of 3,952 patients in the 25 included studies provided data describing coagulation parameters in the less severe and more severe groups. Notably, 23 studies had been conducted in China (11 from Wuhan and 12 from other cities), 1 from Mexico, and 1 from the USA. All the studies were retrospective observational studies and sample size varied from 21 to 577. The median age ranged between 46 and 60 years and the proportion of male patients ranged between 35.3% and 81.0%. Twenty studies followed clinical guidelines (including trial version 4, trial version 5, trial version 7, 6 th edition guidelines, 7 th edition guidelines, and WHO interim guideline) to judge on the disease severity. However, two studies considered whether patients experienced ARDS, and one study considered whether patients experienced ICU care to judge the severity of the disease. The patient characteristics and demographic data for the included studies are shown in Table 1 . The D-dimer, PLT, PT, APTT, and FIB were available in 25, 13, 13, 9, and 5studies respectively. We use the random-effects model due to significant heterogeneity of studies on D-dimer, PLT, PT, and APTT. Notably, D-dimer and PT were significantly higher in more severe patients than in less severe patients (SMD 0.83, 95% CI: 0.70-0.97, I 2 56.9%; SMD 0.39, 95% CI: 0.14-0.64, I 2 77.9% respectively). The fixed-effects model was used due to the insignificant heterogeneity of studies on FIB. The result showed that patients with more severe pneumonia exhibited significantly higher FIB compared to less severe patients (SMD 0.35,95% CI: 0.17-0.53, I 2 42.4%). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2020 16, . . https://doi.org/10.1101 16, /2020 However, no significant difference was observed in PLT and APTT values between severe and mild patients (SMD -0.26, 95% CI: -0.56-0.05, I2 82.2%; SMD -0.14, 95% CI:-0.45-0.18, I2 75.5% respectively). A forest plot of the coagulation parameters is shown in Figure 2 and Figure 3 . Details of the meta-analysis are highlighted in Table 2 . Further, we conducted a subgroup analysis based on location, severity criteria, and age (the median value above and below 50) to determine the sources of heterogeneity. The results for subgroup analysis are presented in Table 3 . Notably, the heterogeneity was significant in the subgroup analyses. However, our subgroup analyses did not explain the observed heterogeneity of studies on D-dimer, PLT, PT, and APTT. Herein, sensitivity analysis showed that the pooled results were not sensitive to any individual study, this confirmed the robustness of the study findings. Detailed results of sensitivity analysis are shown in Supplementary Figure 1 . Also, we assessed publication bias using the funnel plots and Egger's regression test. There was no significant publication bias among the levels of APTT, D-dimer, FIB, PLT, PT in our study (Egger test: P=0.236, P=0.556, P=0.289, P=0.308, P=0 .534 respectively). The funnel diagram and Egger's test are described in Figure 4 . In this work, we revealed that coagulopathy is associated with the severity of COVID-19, and it is characterized by significantly elevated levels of D-dimer, PT, and FIB in more severe cases. This review concurs with the conclusions from the previous meta-analyses on the coagulative function of COVID-19 which found that PT and D-dimer are significantly higher in more severe patients [34] . However, we observed no significant decrease in the levels of PLT in more severe patients. Contrarily, a previous meta-analysis that included nine studies showed an All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2020 16, . . https://doi.org/10.1101 16, /2020 obvious heterogeneity and may lead to unstable results [35] . Moreover, increasing levels of D-dimer and PT indicates that the fibrinolytic system is activated. The coagulation cascade is activated in viral infections as a host defense mechanism to limit the spread of pathogens. Additionally, increased production of cytokines during virus infection stimulates procoagulant reactions that highly express tissue factors, a major initiator that activates coagulation. Besides, endothelial cell activation and damage may alter the natural antithrombotic state given the tropism of Of note, we report the first meta-analysis that assessed the fibrinogen levels on the severity of COVID-19. Similarly, several reports showed that fibrinogen significantly increases in initial and progressive stages of virus infection. Furthermore, a recent report by Ranucci et al [41] indicated comprehensive coagulation analyses on ICU admission with median fibrinogen levels of 7.8 g/L and increased clot strength through thromboelastometry. During the SARS-CoV-2 infection process, a cytokine storm dominated by interleukin-6 occurs [42] , this has been found majorly regulate and stimulate fibrinogen synthesis. Besides, the variation in fibrinogen levels is dependent on the infection stages encountered. Elsewhere, Tang et al [43] reported that fibrinogen levels decline at the late stage of COVID-19 non-survivors despite increased or normal levels on admission, this is potentially caused by sepsis-induced coagulopathy. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2020. . https://doi.org/10. 1101 Despite the obscure mechanism of CAC, abnormal coagulation results including elevated D-dimer and fibrin degradation products are associated with higher COVID-19 mortality rates. Thus, monitoring the levels of coagulation parameters is immensely significant in managing COVID-19. Moreover, Zhou et al [5] conducted a study in 191 patients from Wuhan and found that D-dimer levels higher than 1ug/L are associated with higher in-hospital mortality. The World Health Organization [44] recently issued guidelines for managing COVID-19, whereby it suggested that great focus should be geared on coagulation dysfunction and thrombotic events. Based on our findings, we also suggest that dynamic monitoring of coagulation parameters in hospitalized COVID-19 patients is necessary for predicting progression that is associated with unfavorable outcome and early thrombotic events. Moreover, futures studies should determine whether early anticoagulation features such as low molecular weight heparin (LMWH), warfarin, or new oral anticoagulant (NOAC) are beneficial in patients with significantly elevated coagulation parameters. Besides, our meta-analysis has a few limitations. First, there was obvious heterogeneity among studies regarding definitions of the COVID-19 severity, and either subgroup or sensitivity analyses could not identify the heterogeneity source. Some selected studies did not report using mean and standard deviation, however, they gave estimates by median and quartile which may lead to deviation and effect heterogeneity. We excluded the low-quality studies to maintain the reliability of the conclusion. Second, this meta-analysis was conducted for studies that failed to describe all relevant characteristics of individual patients and it was difficult to adjust on the potentially confounding factors such as comorbidity and treatment (including use of anticoagulation or glucocorticoid). Finally, we included retrospective studies in the meta-analysis and there are risks of bias in the data collected. In conclusion, coagulopathy is associated with the severity of COVID-19. The D-dimer, PT, and FIB are dominant parameters for evaluating coagulopathy in COVID-19. COVID-19 associated coagulopathy has different features from DIC, therefore, it is necessary to closely monitor the dynamics of coagulation parameters. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2020. . https://doi.org/10.1101/2020.07.15.20154138 doi: medRxiv preprint The protocol for this systematic review and meta-analysis has been registered on the Table 1 ). The literature reports were written in English and Chinese. We conducted a literature search on the electronic databases including Pubmed, Embase, Cochrane, WanFang Database, CNKI and medRxiv for reports published from December 1, 2019 to May 1, 2020 using a combination of the following keywords: "COVID-19" or "2019 novel coronavirus infection" or "SARS-CoV-2" and" characteristics" or" coagulopathy" or "coagulation". Besides, we screened and conducted a manual search of the references listed in each article to obtain comprehensive results. The search was done independently by two authors (Xiaolin Zhang and Xue Yang). A third investigator (Hongmei Jiao) came in to resolve any contradicting search results. The inclusion criteria were as follows: (1) Original studies focused on clinical characteristics of patients with COVID-19 including observational study, case-control studies, cohort studies, and randomized control studies; (2) patients were categorized into less and more severe groups; (3) the coagulation parameters between groups were described. Exclusion criteria were as follows: (1) Non-original studies including commentaries, editorials, case reports, letters, meta-analysis, guidelines, and family-based studies; (2) same patients are enrolled in different articles; (3) patients in studies are below 18 years old. Two investigators (Xiaolin Zhang and Xue Yang) independently extracted data and All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2020. . evaluated the quality of literature reports. Contradicting decisions from the two authors were resolved by a third investigator (Hongmei Jiao) or through consensus. Data items extracted from each study included the study characteristics, demographic information, and outcomes of interest. We used the Newcastle-Ottawa scale (NOS) which included patient selection, study comparability, and three components of outcomes assessment to evaluate the quality of the original study. Low-quality articles (NOS<5) were excluded from this meta-analysis. All statistical analyses were performed via Stata 14.0 (Stata, College Station, TX, USA). For continuous variables, we calculated the standard mean difference (SMD) and the 95%CI. Heterogeneity among the studies was assessed using the Chi-squared and I 2 tests. For studies that only reported median and range, CI or interquartile range, we estimated means and SDs as described by Wan [8] . A random-effects model was used when either P<0.05 or I 2 >50% defined significant heterogeneity across the articles. Otherwise, we used the fixed-effects model. A p-value of less than 0.05 was considered significant statistically. Further, a sensitivity analysis was conducted to evaluate the stability of the results and determine the effect of individual study on pooled results. Evidence of publication bias was examined using Egger's regression test for funnel asymmetry in addition to the visual inspection of funnel plots. None. Xiaolin Zhang, Xue Yang, Hongmei Jiao, Xinmin Liu declare that they have no competing interests. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2020. . . L M B , D A W , B Z , B A , M M , L L , N R , G O , M T E , D O T e t a l : T h e e m e r g i n g s p e c t r u m o f c a r d i o p u l m o n a r y p a t h o l o g y o f t h e c o r o n a v i r u s d i s e a s e 2 0 1 9 ( C O V I D -1 9 ) : (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2020. c o r o n a v i r u s d i s e a s e 2 0 1 9 ( C O V I D -1 9 ) : a m e t a -a n a l y s i s . B r J H a e m a t o l 2 0 2 0 . 3 5 . L i p p i G , P l e b a n i M , H e n r y B M : T h r o m b o c y t o p e n i a i s a s s o c i a t e d w i t h s e v e r (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2020. ; 2 0 2 0 . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2020. . https://doi.org/10.1101/2020.07.15.20154138 doi: medRxiv preprint Moderate 212 (72.8%) Severe/critical 50 (17.2%) All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 16, 2020. . https://doi.org/10. 1101 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 16, 2020. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 16, 2020. . https://doi.org/10. 1101